New trial: can hormone pills boost targeted cancer therapy?

NCT ID NCT06654336

Recruiting now Disease control Sponsor: Ontario Clinical Oncology Group (OCOG) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for men whose prostate cancer has come back in a few spots after radiation, but is still hormone-sensitive. Researchers want to see if adding a 12-month course of hormone therapy (ELIGARD) to targeted treatments like radiation or surgery helps keep the cancer from growing longer than targeted treatment alone. About 162 men will take part and be followed for 3 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ELIGARD (hormone therapy) and radiation or surgery
What this could lead to: If successful, this could show that adding short-term hormone therapy to targeted treatment delays cancer progression in men with early recurrent prostate cancer.
What could go wrong: This is a Phase 2 trial with only 162 participants, so results may not apply to everyone. Hormone therapy can cause side effects like hot flashes and fatigue, and the benefit over targeted treatment alone is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION SENSITIVE PROSTATE CANCER PROSTATE ADENOCARCINOMA

Contacts and locations

Locations

Jewish General Hospital
RECRUITING

Montreal, Quebec, H1T2M4, Canada
Juravinski Cancer Centre
RECRUITING

Hamilton, Ontario, Canada
The Ottawa Hospital Regional Cancer Centre
NOT_YET_RECRUITING

Ottawa, Ontario, K1H8L6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.